Company
Since 1909, Grifols has worked to improve the health and well-being of people around the world.
Innovation
Grifols is full speed ahead on developing the next innovative breakthroughs across multiple therapeutic areas.
Sustainability
Grifols' longstanding commitment to people and the planet entails helping society on all fronts.
Investors
Stock Information
Financials
Communications with CNMV and SEC
Corporate Governance
Careers
People are at the heart of our business. We are committed to continued investment in training and development.
Media
Latest news about the company and contact information for journalists and communication professionals.
Partners
At Grifols, we believe in long-term, mutually trusting relationships with our partners.
Connect with us
Showing 492 search results
Grifols and Inpeco joining forces to deliver transfusion medicine ‘lab of the future’
Grifols Phase 2/3 trial shows positive impact of immunoglobulin therapy on post-polio patients
Grifols expects to reach EUR 10 billion in revenue, EUR 2.9 billion in EBITDA and EUR 3.5+ billion in cumulative cash flow by 2029
Grifols delivers a strong 2024 exceeding guidance on revenue and free cash flow
Thomas Glanzmann to retire as Grifols Chairman and will be succeeded by Board member Anne-Catherine Berner
Grifols completes enrollment of second cohort in first-in-human Alpha-1 15% subcutaneous option for treating alpha1-antitrypsin deficiency
Infographic results Full-Year 2024
Grifols collaborates with startup FcR Therapeutics to develop recombinant therapies for autoimmune diseases
Grifols pioneers high-tech analysis of plasma bank to detect early signs of Parkinson’s disease
Grifols submits Biologics License Application for its new fibrinogen solution to U.S. FDA
Grifols announces topline phase 3 data on long-term Albutein® (albumin [human] U.S.P.) therapy for decompensated cirrhosis with ascites
Grifols ranked number one biotech company in Dow Jones Sustainability Indices